Drug Search Results
More Filters [+]

DT-9081

Alternative Names: DT-9081, DT 9081, DT9081
Latest Update: 2024-04-12
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: EP4 Antagonist

Novel Mechanism: Yes

Modality: N/A

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Domain Therapeutics SA
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for DT-9081

Countries in Clinic: Belgium, France

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

EPRAD

P1

Recruiting

Oncology Solid Tumor Unspecified

2025-07-01

Recent News Events